利钠肽检测在呼吸困难中的应用。
Use of natriuretic peptide assay in dyspnea.
机构信息
Departement Innere Medizin, Medizinische Klinik A, Universitätsspital Basel, Petersgraben 4, Basel, Switzerland.
出版信息
Dtsch Arztebl Int. 2008 Feb;105(6):95-100. doi: 10.3238/arztebl.2008.0095. Epub 2008 Feb 8.
Abstract
INTRODUCTION
Acute dyspnea is a common symptom in patients admitted to hospital via emergency department. Heart failure is a common cause with high morbidity and mortality, but diagnostically challenging. Improvement in diagnostic techniques is needed.
METHODS
Selective search of Medline.
RESULTS
B-type natriuretic peptide (BNP) and its N-terminal fragment (NT-proBNP) are extremely helpful in the diagnosis of heart failure in patients with acute dyspnea. The use of natriuretic peptide assay has also been shown to be cost-effective. Since plasma levels of natriuretic peptides reflect the extent of systolic and diastolic dysfunction, measurement of natriuretic peptides is helpful in estimating overall risk in patients with heart failure or acute myocardial infarction. They have also been used in the management of patients with valvular disease and in tailoring therapy in patients with heart failure.
DISCUSSION
BNP and NT-proBNP are quantitative markers of heart failure that are helpful for diagnosis, prognosis and treatment monitoring.
摘要
简介
急性呼吸困难是急诊科收治的患者的常见症状。心力衰竭是一种常见的病因，具有较高的发病率和死亡率，但诊断具有挑战性。需要改进诊断技术。
方法
选择性搜索 Medline。
结果
B 型利钠肽（BNP）及其 N 端片段（NT-proBNP）在急性呼吸困难患者心力衰竭的诊断中非常有帮助。利钠肽检测的应用也被证明具有成本效益。由于利钠肽的血浆水平反映了收缩和舒张功能不全的程度，因此测量利钠肽有助于评估心力衰竭或急性心肌梗死患者的总体风险。它们还用于瓣膜病患者的治疗管理，并用于调整心力衰竭患者的治疗。
讨论
BNP 和 NT-proBNP 是心力衰竭的定量标志物，有助于诊断、预后和治疗监测。
相似文献
1
Use of natriuretic peptide assay in dyspnea.利钠肽检测在呼吸困难中的应用。
Dtsch Arztebl Int. 2008 Feb;105(6):95-100. doi: 10.3238/arztebl.2008.0095. Epub 2008 Feb 8.
2
Plasma N-terminal pro-brain natriuretic peptide and brain natriuretic peptide in assessment of acute dyspnea.血浆N末端脑钠肽前体和脑钠肽在急性呼吸困难评估中的应用
Biomed Pharmacother. 2005 Jan-Feb;59(1-2):20-4. doi: 10.1016/j.biopha.2004.06.002. Epub 2005 Jan 20.
3
[Natriuretic peptides--new diagnostic markers in heart disease].[利钠肽——心脏病的新型诊断标志物]
Herz. 2004 Sep;29(6):609-17. doi: 10.1007/s00059-004-2619-8.
4
[Clinical significance of natriuretic peptides in the differential diagnosis of dyspnea].利钠肽在呼吸困难鉴别诊断中的临床意义
Vnitr Lek. 2016 Fall;62(7-8):640-5.
5
Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP.用于诊断呼吸急促患者急性失代偿性心力衰竭的中段心房利钠肽前体测量：与B型利钠肽（BNP）和氨基末端脑钠肽前体的比较
Clin Chem. 2006 May;52(5):827-31. doi: 10.1373/clinchem.2005.065441. Epub 2006 Mar 16.
6
Midregional pro-atrial natriuretic peptide for the diagnosis of cardiac-related dyspnea according to renal function in the emergency department: a comparison with B-type natriuretic peptide (BNP) and N-terminal proBNP.中段心房利钠肽在急诊根据肾功能诊断与心脏相关的呼吸困难中的应用：与 B 型利钠肽（BNP）和 N 末端 proBNP 的比较。
Clin Chem. 2010 Nov;56(11):1708-17. doi: 10.1373/clinchem.2010.145417. Epub 2010 Sep 2.
7
Pro-B-type natriuretic peptide levels in acute decompensated heart failure.急性失代偿性心力衰竭患者的前B型利钠肽水平
J Am Coll Cardiol. 2008 May 13;51(19):1874-82. doi: 10.1016/j.jacc.2007.12.051.
8
Advances in congestive heart failure management in the intensive care unit: B-type natriuretic peptides in evaluation of acute heart failure.重症监护病房中充血性心力衰竭管理的进展：B型利钠肽在急性心力衰竭评估中的应用
Crit Care Med. 2008 Jan;36(1 Suppl):S17-27. doi: 10.1097/01.CCM.0000296266.74913.85.
9
Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy.体重指数对急性充血性心力衰竭患者利钠肽水平的影响：急诊科呼吸困难的脑钠肽前体研究（PRIDE）子研究
Am Heart J. 2005 Apr;149(4):744-50. doi: 10.1016/j.ahj.2004.07.010.
10
B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure.B型利钠肽和氨基末端脑钠肽前体可独立于急性失代偿性心力衰竭的基线诊断，预测气短患者的一年死亡率。
Clin Chim Acta. 2006 Aug;370(1-2):174-9. doi: 10.1016/j.cca.2006.02.010. Epub 2006 Mar 6.
引用本文的文献
1
ICU 'Magic Numbers': The Role of Biomarkers in Supporting Clinical Decision-Making.重症监护病房的“神奇数字”：生物标志物在支持临床决策中的作用
Diagnostics (Basel). 2025 Apr 11;15(8):975. doi: 10.3390/diagnostics15080975.
2
Clinical Review of Hypertensive Acute Heart Failure.高血压急性心力衰竭的临床综述。
Medicina (Kaunas). 2024 Jan 10;60(1):133. doi: 10.3390/medicina60010133.
3
Natriuretic Peptides as Biomarkers: Narrative Review and Considerations in Cardiovascular and Respiratory Dysfunctions.利钠肽作为生物标志物：在心血管和呼吸功能障碍中的叙述性综述及考虑因素。
Yale J Biol Med. 2023 Mar 31;96(1):137-149. doi: 10.59249/NCST6937. eCollection 2023 Mar.
4
Association of N-terminal pro-brain natriuretic peptide with contrast-induced acute kidney injury and long-term mortality in patients with heart failure and mid-range ejection fraction: An observation study.N末端脑钠肽前体与射血分数中等的心力衰竭患者造影剂诱导的急性肾损伤及长期死亡率的关联：一项观察性研究。
Medicine (Baltimore). 2017 Mar;96(10):e6259. doi: 10.1097/MD.0000000000006259.
5
Numerical parameters and quality indicators in a medical emergency department.医疗急救部门的数值参数和质量指标。
Dtsch Arztebl Int. 2010 Apr;107(15):261-7. doi: 10.3238/arztebl.2010.0261. Epub 2010 Apr 16.
本文引用的文献
1
Long-term prognostic value of B-type natriuretic peptide in cardiac and non-cardiac causes of acute dyspnoea.B型利钠肽在急性呼吸困难的心脏和非心脏病因中的长期预后价值。
Eur J Clin Invest. 2007 Nov;37(11):834-41. doi: 10.1111/j.1365-2362.2007.01871.x. Epub 2007 Oct 11.
2
Multimarker strategy for risk prediction in patients presenting with acute dyspnea to the emergency department.针对急诊科急性呼吸困难患者的多标志物风险预测策略。
Int J Cardiol. 2008 May 7;126(1):73-8. doi: 10.1016/j.ijcard.2007.03.119. Epub 2007 May 3.
3
Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study.血浆脑钠肽指导治疗改善心力衰竭预后：STARS-BNP多中心研究
J Am Coll Cardiol. 2007 Apr 24;49(16):1733-9. doi: 10.1016/j.jacc.2006.10.081. Epub 2007 Apr 2.
4
The integration of BNP and NT-proBNP into clinical medicine.脑钠肽（BNP）和N末端脑钠肽前体（NT-proBNP）在临床医学中的整合应用。
Swiss Med Wkly. 2007 Jan 13;137(1-2):4-12. doi: 10.4414/smw.2007.11614.
5
Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure.慢性阻塞性肺疾病和慢性心力衰竭并存患者的诊断和治疗挑战
J Am Coll Cardiol. 2007 Jan 16;49(2):171-80. doi: 10.1016/j.jacc.2006.08.046. Epub 2006 Dec 29.
6
Gender-specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea: insights from the B-type natriuretic peptide for acute shortness of breath evaluation study.急性呼吸困难患者中基于B型利钠肽水平的性别特异性风险分层：来自B型利钠肽用于急性呼吸急促评估研究的见解
J Am Coll Cardiol. 2006 Nov 7;48(9):1808-12. doi: 10.1016/j.jacc.2006.07.037. Epub 2006 Oct 17.
7
B-type natriuretic peptide levels predict event-free survival in patients with implantable cardioverter defibrillators.B型利钠肽水平可预测植入式心脏复律除颤器患者的无事件生存期。
Eur J Heart Fail. 2007 Mar;9(3):272-9. doi: 10.1016/j.ejheart.2006.07.004. Epub 2006 Oct 5.
8
Prognostic value of N-terminal pro-B-type natriuretic peptide for conservatively and surgically treated patients with aortic valve stenosis.N端前B型利钠肽对主动脉瓣狭窄保守治疗和手术治疗患者的预后价值
Heart. 2006 Nov;92(11):1639-44. doi: 10.1136/hrt.2005.085506. Epub 2006 Jun 1.
9
Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea.急性呼吸困难患者B型利钠肽检测的成本效益
Arch Intern Med. 2006 May 22;166(10):1081-7. doi: 10.1001/archinte.166.10.1081.
10
Does this dyspneic patient in the emergency department have congestive heart failure?这位在急诊科出现呼吸困难的患者是否患有充血性心力衰竭？
JAMA. 2005 Oct 19;294(15):1944-56. doi: 10.1001/jama.294.15.1944.
Zotero 插件